iMMUNOLOGY tODAY

Author Index

Subject Index

Index of Books Reviewed

1997

Vol 18
Issues 1–12

ISSN 0167-5699

Immunology Today

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410
E-mail: IT@elsevier.co.uk

Advisory Editorial Board
J.D. Ashwell, *Bethesda, USA*
F.H. Bach, *Harvard, USA*
J.F. Bach, *Paris, France*
T. Boon, *Brussels, Belgium*
C.A. Janeway, Jr, *New Haven, USA*
T. Kishimoto, *Osaka, Japan*
D. Mathis, *Strasbourg, France*
F. Melchers, *Basel, Switzerland*
T. Mosmann, *Edmonton, Canada*
G.J.V. Nossal, *Melbourne, Australia*
A. Rao, *Boston, USA*
K.B.M. Reid, *Oxford, UK*
E. Simpson, *Harrow, UK*
R. Zinkernagel, *Zürich, Switzerland*

Editor Robert Brines

Assistant Editor Louise Walsh

Editorial Administrator Hannah Ruczaj

Publisher Peter Desmond

© 1998 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Author Index

(BR): Book Review
(L): Letter to the Editor

A
Accolla, R., HLA and MHC: Genes, Molecules and Function (BR) 200
Achey, K., *see* Wakeland, E. 472
Adorini, L. and Sinigaglia, F., Pathogenesis and immunotherapy of autoimmune diseases 209
Ahne, W., Invertebrate Immunology (BR) 199
Akbar, A.M. and Salmon, M., Cellular environments and apoptosis: tissue microenvironments control activated T-cell death 72
Akhand, A.A., *see* Nakashima, I. (L) 362
Allen, J.E. and Maizels, R., Th1–Th2 paradigm: reliable paradigm or dangerous dogma? 387
Altman, A., *see* Collins, T.L. 221
Amadori, A., Zamarchi, R. and Chieco-Bianchi, L., Reply to Cole (L) 506
Amadori, A., Zanarchi, R. and Chieco-Bianchi, L., Reply to Bostik *et al.* (L) 556
Amor, S., Baker, D., Layward, L., McCormack, K. and van Noort, J.M., Multiple sclerosis: variations on a theme 368
Anderson, G. and Jenkinson, E., Piecing together the thymic puzzle 363
Ansari, A.A., *see* Bostik, P. (L) 555
Ardavin, C., Thymic dendritic cells 350
Aruffo, A., Bowen, M.A., Patel, D.D., Haynes, B.F., Starling, G.C., Glebe, J.A. and Bajorath, J., CD6–ligand interactions: a paradigm for SRCR domain function? 498
Arulampalam, V., Eckhardt, L. and Pettersson, S., The enhancer shift: a model to explain the developmental control of IgH gene expression in B-lineage cells 549
Asselin-Paturel, C., *see* Chouaib, S. 493
Axford, J.S., 4th Jenner International Glycoimmunology Meeting 511

B
Bach, F., Hancock, W.W. and Ferran, C., Protective genes expressed in endothelial cells: a regulatory response to injury 483
Bajorath, J., *see* Aruffo, A. 498
Baker, D., *see* Amor, S. 368
Bast, B., *see* van de Winkel, J.G.J. 562
Baum, H., Davies, H. and Peakman, M., Database screening for molecular mimicry (L) 252
Belardelli, F., *see* Fais, S., 522
Bender, J.R., *see* Bianchi, E. 586
Benichou, G.A., Tam, R.C., Soares, L.R.B. and Fedoseyeva, E.V., Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation 67
Bercovici, N., *see* Liblau, R. 599
Bernstein, R.M., *see* Schluter, S.F. 543
Beurskens, F.J.M., van Dijk, H. and Robins, D.M., Does complement component C4A protect from autoimmune disease? (L) 199
Beverley, P.C.L., Vaccine immunity 413
Bianchi, E., Bender, J.R., Blasi, F. and Pardi, R., Through and beyond the wall: late steps in leukocyte transendothelial migration 586
Bieber, T., FcεRI-expressing antigen-presenting cells: new players in the atopic game 311
Bishop, G.A., McCaughan, G.W., Sun, J. and Sheil, A.G.R., Microchimerism and transplant tolerance (L) 455
Blackman, M.A., *see* Woodland, D.L. 18
Blasi, F., uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? 415
Blasi, F., *see* Bianchi, E. 586
Blay, J-Y., *see* Chouaib, S. 493
Bluethmann, H., *see* Gutierrez-Ramos, J.C. 329
Bonnefoy, J-Y., *see* Kosco-Vilbois, M. 225
Boon, T., Coulie, P.G. and Van den Eynde, B., Tumor antigens recognized by T cells 267
Bostik, P., Villinger, F., Ansari, A.A. and Folkes, T.M., Pre-infection $CD4^+$:$CD8^+$ ratio and HIV infection (L) 555
Bousquet, J., Allergic Diseases: Diagnosis and Treatment (BR) 408
Bowen, M.A., *see* Aruffo, A. 498
Brabb, T., *see* Goverman, J. 204
Bruck, C., *see* Heeney, J.L. 4
Brusic, V., Rudy, G. and Harrison, L.C., Molecular mimicry – from hypothesis towards evidence (L) 95
Burgio, V.L., *see* Fais, S. 522
Burns, W.H., *see* Burt, R.K. 559
Burt, R.K., Burns, W.H. and Miller, S.D., Bone-marrow transplantation for multiple sclerosis: returning to Pandora's box 559
Bussolino, F., *see* Mantovani, A. 231

C
Cabrera, T., *see* Garrido, F. 89
Caignard, A., *see* Chouaib, S. 493
Capobianchi, M.R., *see* Fais, S. 522
Carayanniotis, G. and Rao, V.P., Searching for pathogenic epitopes in thyroglobulin: parameters and caveats 83
Cassone, A., Conti, S., De Bernardis, F. and Polonelli, L., Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? 164
Catania, A., *see* Lipton, J.M. 140
Cavallo, F., *see* Musiani, P. 32
Chaouat, G., *see* King, A. 64
Chick, W.L., *see* Lanza, R.P. 135
Chieco-Bianchi, L., *see* Amadori, A. (L) 506
Chieco-Bianchi, L., *see* Amadori, A. (L) 556
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A. and Blay, J-Y., The host–tumor immune conflict: from immunosuppression to resistance and destruction 493
Christmas, S.E., *see* Johnson, P.M. (L) 605
Clark, M., The Web Publisher's Illustrated Quick Reference (BR) 457
Clementi, E., *see* Fortis, C. (L) 254
Clevers, H., European immunologists meet in Amsterdam 257
Coggeshall, K.M., *see* Tridandapani, S. 424
Cole, S., Blind T-cell homeostasis and HIV infection (L) 505
Collette, Y. and Olive, D., Non-receptor tyrosine kinases as immune targets of viruses 393
Collins, T.L., Deckert, M. and Altman, A., Views on Vav 221
Colombo, M.P., *see* Musiani, P. 32
Conti, S., *see* Cassone, A. 164
Cook, G., Immunobiology: The Immune System in Health and Disease (2nd edn) (BR) 201
Cooney, D., *see* Tridandapani, S. 424
Cordero, O.J., Rainer Maurer, H.R. and Nogueira, M., Novel approaches to immunotherapy using thymic peptides 10
Coulie, P.G., *see* Boon, T. 267
Cunningham, P., *see* Wilson, C. (L) 96

D
Daëron, M., *see* Vivier, E. 286
Dana, M-R., *see* Streilein, J.W. 443
David, B., *see* Mécheri, S. 212
Davies, H., *see* Baum, H. (L) 252
De Bernardis, F., *see* Cassone, A. 164
de Gast, G.C., *see* van de Winkel, J.G.J. 562
de Groot, C., *see* Lindhout, E. 573
De Libero, G., Sentinel function of broadly reactive human γδ T cells 22
de Rijk, R., *see* Wilckens, T. 418

de Smet, B.J.G.L., *see* Laman, J.D. 272
Deckert, M., *see* Collins, T.L. 221
Denisova, G., *see* Gershoni, J.M. 108
Deo, Y.M., Graziano, R.F., Repp, R. and van de Winkel, J.G.J., Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies 127
Dierich, M.P., *see* Würzner, R. 460
Dinarello, C.A., *see* Tilg, H. 428
Duggan-Keen, M., *see* Garrido, F. 89
Doherty, P.C., *see* Zinkernagel, R.M. 14
Dunon, D., Poultry Immunology (BR) 307
Duyster, J., *see* Gruss, H-J. 156

E
Ebringer, A., *see* Wilson, C. (L) 96
Eckhardt, L., *see* Arulampalam, V. 549
Edwards, S.W. and Hallett, M.B., Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis 320
Effros, R.B. and Pawelec, G., Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? 450
Eggert, F., *see* Zavazava, N. 8
Ehrhardt, R., *see* Strober, W. 61
Eigler, A., Sinha, B., Hartmann, G. and Endres, S., Taming TNF: strategies to restrain this proinflammatory cytokine 487
Elliott, T., How does TAP associate with MHC class I molecules? 375
Endres, S., *see* Eigler, A. 487
Ettelaie, C., *see* Wilson, C. (L) 96

F
Fairchild, P.J. and Wraith, D.C., Reply to van der Burg *et al.* (L) 98
Fais, S., Burgio, V.L., Capobianchi, M.R., Gessani, S., Pallone, F. and Belardelli, F., The biological relevance of polykaryons in the immune response 522
Fan, J-L., *see* Prabhakar, B.S. 437
Farr, A.G., *see* Goverman, J. 204
Farrant, J., *see* Spickett, G.P. 325
Fedoseyeva, E.V., *see* Benichou, G.A. 67
Ferguson, T.A., *see* Griffith, T.S. 240
Ferguson, T.A., *see* Griffith, T.S. 361
Ferran, C., *see* Bach, F. 483
Ferrone, S., *see* Puppo, F. 154
Ferrone, S., *see* Seliger, B. 292
Finkelman, F., *see* Gause, W.C. 115
Finn, O., *see* Taylor-Papadimitriou, J. 105
Flynn, J.N., *see* Willett, B.J. 182
Folkes, T.M., *see* Bostik, P. (L) 555
Forni, G., *see* Musiani, P. 32
Fortis, C. and Clementi, E., Reversible lymphocyte anergy during IL-2 therapy (L) 254
Franceschi, C., *see* Ottaviani, E. 169
Fresno, M., Kopf, M. and Rivas, L., Cytokines and infectious diseases 56
Fridkis-Hareli, M., *see* Mehr, R. 581
Friend, P., Transplantation Immunology (BR) 409
Fry, J.W., Gilot, B.J. and Wood, K.W., A History of Transplantation Immunology (BR) 409
Fuss, I., *see* Strober, W. 61

G
Galili, U. and LaTemple, D.C., Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity 281
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J.J. and Lopez-Botet, M., Duggan-Keen, M., Stern, P.L., Implications for immunosurveillance of altered HLA class I phenotypes in human tumours 89
Gause, W.C., Halvorson, M.J., Lu, P., Greenwald, R., Linsley, P., Urban, J.F. and Finkelman, F., The function of costimulatory molecules and the development of IL-4-producing T cells 115
Gerdes, J., *see* Kosco-Vilbois, M. 225
Gershoni, J.M., Stern, B. and Denisova, G., Combinatorial libraries, epitope structure and the prediction of protein conformations 108
Gessani, S., *see* Fais, S. 522
Ghetie, V. and Ward, E.S., FcRn: the MHC class I-related receptor that is more than an IgG transporter 592
Gilot, B.J., *see* Fry, J.W. (BR) 409
Giovarelli, M., *see* Musiani, P. 32
Girolomoni, G. and Ricciardi-Castagnoli, P., Dendritic cells hold promise for immunotherapy 102
Glebe, J.A., *see* Aruffo, A. 498
Globerson, A., *see* Mehr, R. 581
Goldman, M., *see* Pretolani, M. 277
Goldstein, B. and Wofsy, C., Reply to Hubble (L) 306
Goudsmit, J., *see* Heeney, J.L. 4
Goverman, J., Brabb, T., Huseby, E.S. and Farr, A.G., TCR signaling regulates thymic organization: lessons from TCR-transgenic mice 204
Gray, J.D., *see* Horwitz, D.A. 538
Graziano, R.F., *see* Deo, Y.M. 127
Greenwald, R., *see* Gause, W.C. 115
Gress, R.E., *see* Mackall, C.L. 245
Griffith, T.S. and Ferguson, T., Erratum 361
Griffith, T.S. and Ferguson, T.A., The role of FAS ligand-induced apopotosis in immune privilege 240
Gruss, H-J., Pinto, A., Duyster, J., Poppema, S. and Herrmann, F., Hodgkin's disease: a tumor with disturbed immunological pathways 156
Gutierrez-Ramos, J.C. and Bluethmann, H., Molecules and mechanisms operating in septic shock: lessons from knockout mice 329

H
Hack, C.E., Wolbink, G-J., Schalkwijk, C., Speijer, H., Hermens, W.Th. and van den Bosch, H., A role for secretory phospholipase A_2 and C-reactive protein in the removal of injured cells 111
Hakim, F.T., *see* Mackall, C.L. 245
Hallett, M.B., *see* Edwards, S.W. 320
Halvorson, M.J., *see* Gause, W.C. 115
Hamilton, J.A., CSF-1 signal transduction: what is of functional significance? 313
Hämmerling, G.J., *see* Kropshofer, H. 77
Hancock, W.W., *see* Bach, F. 483
Harrison, L.C., *see* Brusic, V. (L) 95
Hartmann, G., *see* Eigler, A. 487
Haynes, B.F., *see* Aruffo, A. 498
Heeney, J.L., Bruck, C., Goudsmit, J., Montagnier, L., Schultz, A., Tyrrell, D. and Zolla-Pazner, S., Immune correlates of protection from HIV infection and AIDS 4
Hengartner, H., *see* Zinkernagel, R.M. 258
Hermens, W.Th., *see* Hack, C.E. 111
Herrmann, F., *see* Gruss, H-J. 156
Hintzen, R.Q. and Polman, C.H., Th cell modulation in multiple sclerosis (L) 507
Hirokawa, M., *see* Horwitz, D.A. 538
Hopkins, J., *see* Naessens, J. 365
Horwitz, D.A., Gray, J.D., Ohtsuka, K., Hirokawa, M. and Takahashi, T., The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity 538
Hosie, M.J., *see* Willett, B.J. 182
Howard, C.J., *see* Naessens, J. 365
Hubble, J., Dissociation of multivalent antibody–antigen interactions (L) 305
Huseby, E.S., *see* Goverman, J. 204

I
Indiveri, F., *see* Puppo, F. 154
Introna, M., *see* Mantovani, A. 231
Isenberg, D.A., Rahman, M.A., Ravirajan, C.T. and Kalsi, J.K., Anti-DNA antibodies: from gene usage to crystal structures 149

J
Jacobs, H., Pre-TCR/CD3 and TCR/CD3 complexes: decamers with differential signalling properties? 565
Jenkinson, E., *see* Anderson, G. 363
Johnson, P.M., Vince, G.S. and Christmas, S.E., NK cells and reproduction (L) 605

K
Kalsi, J.K., *see* Isenberg, D.A. 149
Kato, M., *see* Nakashima, I. (L) 362
Kelly, T., *see* Tridandapani, S. 424
Kelsall, B., *see* Strober, W. 61
King, A., Loke, Y.W. and Chaouat, G., NK cells and reproduction 64
Kioussis, D., *see* Williams, O. 121
Kirchner, H., *see* Wellinghausen, N. 519

Koopman, G., *see* Lindhout, E. 573
Kopf, M., *see* Fresno, M. 56
Koretzky, G.A., The role of Grb2-associated proteins in T-cell activation 401
Kosco-Vilbois, M., Zentgraf, H., Gerdes, J. and Bonnefoy, J-Y., To 'B' or not to 'B' a germinal center? 225
Krensky, A.M., *see* Ortiz, B.D. 468
Kroemer, G., Zamzami, N. and Susin, S.A., Mitochondrial control of apoptosis 44
Kropshofer, H., Hämmerling, G.J. and Vogt, A.B., How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? 77
Ksander, B.R., *see* Streilein, J.W. 443

L
Laman, J.D., de Smet, B.J.G.L., Schoneveld, A. and van Meurs, M., CD40–CD40L interactions in atherosclerosis 272
Landry, S.J., Local protein instability predictive of helper T-cell epitopes 527
Lanza, R.P. and Chick, W.L., Immunoisolation: at a turning point 135
Lanzavecchia, A., *see* Valitutti, S. 299
LaTemple, D.C., *see* Galili, U. 281
Layward, L., *see* Amor, S. 368
LeFranc, M-P., Unique database numbering system for immunogenetic analysis 509
Liblau, R., Tisch, R., Bercovici, N. and McDevitt, H.O., Systemic antigen in the treatment of T-cell-mediated autoimmune diseases 599
Lindhout, E., Koopman, G., Pals, S.T. and de Groot, C., Triple check for antigen specificity of B cells during germinal centre reactions 573
Linsley, P., *see* Gause, W.C. 115
Lipsky, P.E., *see* Oppenheimer-Marks, N. (L) 456
Lipton, J.M. and Catania, A., Anti-inflammatory actions of the neuroimmunomodulator α-MSH 140
Liu, Y., Is CTLA-4 a negative regulator for T-cell activation? 569
Locksley, R., Immunity to Parasites: How parasitic infections are controlled (2nd edn) (BR) 255
Loke, Y.W, *see* King, A. 64
Lollini, P.L., *see* Musiani, P., 32
Longmate, J., *see* Wakeland, E. 472
Lopez-Botet, M., *see* Garrido, F. 89
Lu, P., *see* Gause, W.C. 115
Ludviksson, B., *see* Strober, W. 61

M
Mackall, C.L., Hakim, F.T. and Gress, R.E., T-cell regeneration: all repertoires are not created equal 245
Maeurer, M.J., *see* Seliger, B. 292
Maizels, R., *see* Allen, J.E. 387
Mami-Chouaib, F., *see* Chouaib, S. 493
Mantovani, A., Bussolino, F. and Introna, M., Cytokine regulation of endothelial cell function: from molecular level to the bedside 231
Marchalonis, J.J., *see* Schluter, S.F. 543
Marcinkiewicz, J., Neutrophil chloramines: missing links between innate and acquired immunity 577
Marth, T., *see* Strober, W. 61
May, J., *see* Meyer, C.G. 58
McCaughan, G.W., *see* Bishop, G.A. (L) 455
McCormack, K., *see* Amor, S. 368
McDevitt, H.O., *see* Liblau, R. 599
Mécheri, S. and David, B., Unravelling the mast cell dilemma: culprit or victim of its generosity? 212
Medd, P.G. and Woodhead, V.E., Towards a new horizon 516
Mehr, R., Perelson, A.S., Fridkis-Hareli, M. and Globerson, A., Regulatory feedback pathways in the thymus 581
Melief, C.J.M., *see* van der Burg, S.H. (L) 97
Meyer, C.G., May, J. and Schnittger, L., HLA-DP – part of the concert 58
Mier, J.W., *see* Tilg, H. 428
Miller, S.D., *see* Burt, R.K. 559
Modesti, A., *see* Musiani, P. 32
Montagnier, L., *see* Heeney, J.L. 4
Morel, L., *see* Wakeland, E. 472
Morgan, L., *see* Spickett, G.P. 325
Morhenn, V.B., Langerhans cells may trigger the psoriatic disease process via production of nitric oxide 433
Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M.P., Lollini, P.L. and Forni, G., Cytokines, tumour cell death and immunogenicity: a question of choice 32

N
Naessens, J., Howard, C.J. and Hopkins, J., Nomenclature and characterization of leukocyte differentiation antigens in ruminants 365
Nakashima, I., Pu, M-y., Akhand, A.A., Kato, M. and Suzuki, H., Chemical events in signal transduction (L) 362
Nall, B.T., *see* Raaphorst, F.M. 37
Nelson, P.J., *see* Ortiz, B.D. 468
Neurath, M., *see* Strober, W. 61
Nogueira, M., *see* Cordero, O.J. 10
North, M.E., *see* Spickett, G.P. 325
Nossal, G.J.V., *see* Pulendran, B. 27
Nowak, M.A., *see* Stekel, D.J. 216

O
O'Gorman, M.R.G., Case Studies in Immunology: A Clinical Companion (BR) 254
Offringa, R., *see* van der Burg, S.H. (L) 97
Ohtsuka, K., *see* Horwitz, D.A. 538
Olive, D., *see* Collette, Y. 393
Oppenheimer-Marks, N. and Lipsky, P.E., Migration of naive and memory T cells (L) 456
Ortiz, B.D., Nelson, P.J. and Krensky, A.M., Switching gears during T-cell maturation: RANTES and late transcription 468
Ottaviani, E. and Franceschi, C., The invertebrate phagocytic immunocyte: clues to a common evolution of immune and neuroendocrine systems 169

P
Pallone, F., *see* Fais, S. 522
Pals, S.T., *see* Lindhout, E. 573
Panerai, A.E. and Sacerdote, P., β-endorphin in the immune system: a role at last? 317
Pardi, R., *see* Bianchi, E. 586
Parker, C.E., *see* Stekel, D.J. 216
Patel, D.D., *see* Aruffo, A. 498
Pathak, S.S. and Savelkoul, H.F.J., Biosensors in immunology: the story so far 464
Pawelec, G. and Solana, R., Immunosenescence 514
Pawelec, G., *see* Effros, R.B. 450
Peakman, M., *see* Baum, H. (L) 252
Perelson, A.S., *see* Mehr, R. 581
Pérez-Villar, J.J., *see* Garrido, F. 89
Pettersson, S., *see* Arulampalam, V. 549
Pinto, A., *see* Gruss, H-J. 156
Pistoia, V., Production of cytokines by human B cells in health and disease 343
Ploegh, H.L., Destruction of proteins as a creative force 269
Plytycz, B. and Seljelid, R., B-1/macrophages as 'living fossils' (L) 505
Polman, C.H., *see* Hintzen, R.Q. (L) 507
Polonelli, L., *see* Cassone, A. 164
Poppema, S., *see* Gruss, H-J. 156
Prabhakar, B.S., Fan, J-L. and Seetharamaiah, G.S., Thyrotropin-receptor-mediated diseases: a paradigm for receptor autoimmunity 437
Pradhan, M., *see* Tridandapani, S. 424
Pretolani, M. and Goldman, M., IL-10: a potential therapy for allergic inflammation? 277
Pu, M-y., *see* Nakashima, I. (L) 362
Pulendran, B., van Driel, R. and Nossal, G.J.V., Immunological tolerance in germinal centres 27
Puppo, F., Indiveri, F., Scudeletti, M. and Ferrone, S., Soluble HLA antigens: new roles and uses 154

R
Raaphorst, F.M., Raman, C.S., Nall, B.T. and Teale, J.M., Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes 37
Raghupathy, R., Th1-type immunity is incompatible with successful pregnancy 478

Rahman, M.A., *see* Isenberg, D.A. 149
Rainer Maurer, H.R., *see* Cordero, O.J. 10
Raman, C.S., *see* Raaphorst, F.M. 37
Rao, V.P., *see* Carayanniotis, G. 83
Ravirajan, C.T., *see* Isenberg, D.A. 149
Repp, R., *see* Deo, Y.M. 127
Resta, R. and Thompson, L.F., SCID: the role of adenosine deaminase deficiency 371
Ricciardi-Castagnoli, P., *see* Girolomoni, G. 102
Rink, L., *see* Wellinghausen, N. 519
Ristori, G. and Salvetti, M., Frontiers in Multiple Sclerosis: Clinical Research and Therapy (BR) 306
Rivas, L., *see* Fresno, M. 56
Robins, D.M., *see* Beurskens, F.J.M. (L) 199
Romagnani, S., The Th1/Th2 paradigm 263
Romball, C.G., *see* Weigle, W.O. 533
Rosenberg, S.A., Cancer vaccines based on the identification of genes encoding cancer regression antigens 175
Roudier, J., Reply to Wildner *et al.* and Baum *et al.* (L) 253
Rovin, B.H., Immunologic Renal Diseases (BR) 508
Rudy, G., *see* Brusic, V. (L) 95
Ruiz-Cabello, F., *see* Garrido, F. 89

S
Sacerdote, P., *see* Panerai, A.E. 317
Salmon, M., *see* Akbar, A.M. 72
Salvetti, M., *see* Ristori, G. (BR) 306
Savelkoul, H.F.J., *see* Pathak, S.S. 464
Saxena, R.K., Ontogeny of inhibitory receptors for MHC molecules on NK cells (L) 146
Schalkwijk, C., *see* Hack, C.E. 111
Schluter, S.F., Bernstein, R.M. and Marchalonis, J.J., Molecular origins and evolution of immunoglobulin heavy-chain genes of jawed vertebrates 543
Schnittger, L., *see* Meyer, C.G. 58
Schoneveld, A., *see* Laman, J.D. 272
Schultz, A., *see* Heeney, J.L. 4
Scudeletti, M., *see* Puppo, F. 154
Seetharamaiah, G.S., *see* Prabhakar, B.S. 437
Seliger, B., Maeurer, M.J. and Ferrone, S., Tap off – tumors on 292
Seljelid, R., *see* Plytycz, B. (L) 505
Shaw, S., PROW: controlling the flood of biological information
Sheil, A.G.R., *see* Bishop, G.A. (L) 455
Siegl, E., The Fish Immune System: Organism, Pathogen, and Environment (BR) 556
Silverman, G.J., B-cell superantigens 379
Sinha, B., *see* Eigler, A. 487
Sinigaglia, F., *see* Adorini, L. 209
Sittinger, M., Principles of Tissue Engineering (BR) 407
Smith, R., Basic and Clinical Immunology (BR) 606
Soares, L.R.B., *see* Benichou, G.A. 67
Solana, R., *see* Pawelec, G. 514
Speijer, H., *see* Hack, C.E. 111
Spickett, G.P., Farrant, J., North, M.E., Zhang, J-G., Morgan, L. and Webster, A.D.B., Common variable immunodeficiency: how many diseases? 325
Starling, G.C., *see* Aruffo, A. 498
Stekel, D.J., Parker, C.E. and Nowak, M.A., A model of lymphocyte recirculation 216
Stern, B., *see* Gershoni, J.M. 108
Stern, P.L., *see* Garrido, F. 89
Streilein, J.W., Dana, M-R. and Ksander, B.R., Immunity causing blindness: five different paths to herpes stromal keratitis 443
Strober, W., Kelsall, B., Fuss, I., Marth, T., Ludviksson, B., Ehrhardt, R. and Neurath, M., Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation 61
Sun, J., *see* Bishop, G.A. (L) 455
Susin, S.A., *see* Kroemer, G. 44
Suzuki, H., *see* Nakashima, I. (L) 362

T
Takahashi, T., *see* Horwitz, D.A. 538
Tam, R.C., *see* Benichou, G.A. 67
Tanaka, Y., *see* Williams, O. 121
Tarazona, R., *see* Williams, O. 121
Taylor-Papadimitriou, J. and Finn, O., Biology, biochemistry and immunology of carcinoma-associated mucins 105
Teale, J.M., *see* Raaphorst, F.M. 37
Thompson, L.F., *see* Resta, R. 371
Thurau, S., *see* Wildner, G. (L) 252
Tilg, H., Dinarello, C.A. and Mier, J.W., IL-6 and APPs: anti-inflammatory and immunosuppressive mediators 428
Tisch, R., *see* Liblau, R. 599
Tiwana, H., *see* Wilson, C. (L) 96
Tomlinson, I., Immunoglobulin Genes (2nd edn) (BR) 200
Tridandapani, S., Kelly, T., Cooney, D., Pradhan, M. and Coggeshall, K.M., Negative signaling in B cells: SHIP Grbs Shc 424
Turke, P.W., Thymic involution (L) 407
Turner, M., Mannose-binding lectin: the pleuripotent molecule of the innate immune system 98
Tyrrell, D., *see* Henney, J.L. 4

U
Urban, J.F., *see* Gause, W.C. 115

V
Valitutti, S. and Lanzavecchia, A., Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition 299
van den Bosch, H., *see* Hack, C.E. 111
van de Winkel, J.G.J., *see* Deo, Y.M. 127
van de Winkel, J.G.J, Bast, B. and de Gast, G.C., Immunotherapeutic potential of bispecific antibodies 562
Van den Eynde, B., *see* Boon, T. 267
van der Burg, S.H., Visseren, M.J.W., Offringa, R. and Melief, C.J.M., Do epitopes derived from autoantigens display low affinity for MHC class I? (L) 97
van Dijk, H., *see* Beurskens, F.J.M. (L) 199
van Driel, R., *see* Pulendran, B. 27
van Meurs, M., *see* Laman, J.D. 272
van Noort, J.M., *see* Amor, S. 368
Villinger, F., *see* Bostik, P. (L) 555
Vince, G.S., *see* Johnson, P.M. (L) 605
Visseren, M.J.W., *see* van der Burg, S.H. (L) 97
Vivier, E. and Daëron, M., Immunoreceptor tyrosine-based inhibition motifs 286
Vogt, A.B., *see* Kropshofer, H. 77
von Boehmer, H., Aspects of lymphocyte developmental biology 260

W
Wakeland, E., Morel, L., Achey, K., Yui, M. and Longmate, J., Speed congenics: a classic technique in the fast lane 472
Walsh, L, Cancer therapy via ceramide-mediated apoptosis 558
Ward, E.S., *see* Ghetie, V. 592
Webster, A.D.B., *see* Spickett, G.P. 325
Weigle, W.O. and Romball, C.G., $CD4^+$ T-cell subsets and cytokines involved in peripheral tolerance 533
Weiner, H.L., Oral tolerance: immune mechanisms and treatment of autoimmune diseases 335
Weissman, A.M., Regulating protein degradation by ubiquitination 189
Wellinghausen, N., Kirchner, H. and Rink, L., The immunobiology of zinc 519
Wen, R., *see* Woodland, D.L. 18
Wilckens, T. and De Rijk, R., Glucocorticoids and immune function: unknown dimensions and new frontiers 418
Wildner, G. and Thurau, S., Database screening for molecular mimicry (L) 252
Willett, B.J., Flynn, J.N. and Hosie, M.J., FIV infection of the domestic cat: an animal model for AIDS 182
Williams, O., Tanaka, Y., Tarazona, R. and Kioussis, D., The agonist–antagonist balance in positive selection 121
Wilson, C., Cunningham, P., Ettelaie, C., Tiwana, H. and Ebringer, A., HLA-DR4 restriction, molecular mimicry and rheumatoid arthritis (L) 96
Wofsy, C., *see* Goldstein, B. (L) 306
Wolbink, G-J., *see* Hack, C.E. 111
Wood, K.W., *see* Fry, J.W. (BR) 409
Woodhead, V.E., *see* Medd, P.G. 516

Woodland, D.L., Wen, R. and Blackman, M.A., Why do superantigens care about peptides? 18
Wraith, D.C., *see* Fairchild, P.J. (L) 98
Würzner, R. and Dierich, M.P., Complement: the Iceman of Immunology? 460

Y
Yui, M., *see* Wakeland, E. 472

Z
Zamarchi, R., *see* Amadori, A. (L) 506
Zamzami, N., *see* Kroemer, G. 44
Zanarchi, R., *see* Amadori, A. (L) 556
Zavazava, N. and Eggert, F., MHC and behavior 8
Zentgraf, H., *see* Kosco-Vilbois, M. 225
Zhang, J-G., *see* Spickett, G.P. 325
Zinkernagel, R.M. and Doherty, P.C., The discovery of MHC restriction 14
Zinkernagel, R.M. and Hengartner, H., Antiviral immunity 258
Zolla-Pazner, S., *see* Heeney, J.L. 4

Subject Index

References are to page numbers.
The suffix (L) = Letter to the Editor.
Alphabetization is letter-by-letter e.g.
T cells
T-cell vaccination

A
α-1,3-galactosyltransferase (α-1,3-GT)
augmenting tumor immunogenicity 283
synthesis of α-gal epitopes 281
Accommodation
in xenotransplantation 483
Acquired immunodeficiency syndrome *see* AIDS
Activation induced cell death (AICD) *see also* Apoptosis
cytokine deprivation and 75
Acute anterior uveitis
oral tolerance in 340
Acute phase proteins (APPs) *see also* Acute phase response
and IL-6 as anti-inflammatory mediators 428–432
Acute phase response *see also* Acute phase proteins
C-reactive protein 111–115
glucocorticoids and 419
secretory phospholipase A_2 111–115
C-reactive protein 111–115
Adenosine deaminase (ADA)
-deficiency in SCID 371–374
Adhesion molecule
CD6–ALCAM interactions 498–504
in leukocyte migration 587, 588
Agonist
peptides in TCR selection 121–126
AICD *see* Activation-induced cell death
AIDS *see also* FIV, HIV
adult versus pediatric 310
complement deficiencies in 461
feline model 182–189
T-cell homeostasis in 505–507 (L), 555–556 (L)
Th1 and Th2 in 264
ALCAM
–CD6 interactions 498–504
Allergy
FcεRI expression on APC 311–313
role of complement 461
Th1 and Th2 cells in 265
Alloantigen
indirect T-cell recognition of 67–71
Altered peptide ligand (APL)
in positive selection 121–126
serial engagement of TCR by 301
Anergy *see also* Tolerance
during IL-2 immunotherapy 254 (L)
Antagonist
peptides in TCR selection 121–126
Anti-DNA antibodies
structure, pathogenic role 149–153
Antibody
anti-fungal responses 164–168
bispecific, in immunotherapy 562–564
natural anti-Gal in tumor immunotherapy 281–285
Antigen
for γδ T cells 22–26
epitope prediction 527–532
systemic, in treatment of autoimmune disease 599–604
Antigen dissociation
from cell-surface antibodies 305 (L), 306 (L)
Antigen presentation *see also* Antigen-presenting cell
for production of anti-DNA antibodies 150
HLA-DM and peptide repertoire editing 77–82
recent advances in 269–271
to TCR/CD3 complex, a model 566
Antigen-presenting cell *see also* Dendritic cell, Follicular dendritic cell, Langerhans cell, Thymic dendritic cells
dendritic cells in immunotherapy 102–104
FcεRI expression in atopy 311–313
in tolerance induction 535
Antigen processing
abnormalities in cancer 292–299
TAP–MHC class I association 375–379
recent advances in 269–271
role of ubiquitination 189–198
Antigen recognition
serial engagement of TCR in 299–304
Antigen specificity
checkpoints during GC reactions 573–577
Antiviral immunity
oncogenic viruses and 268
recent advances 258–260
role of Th1 cells 389
viral evasion of proteasome activity 270
AP-1
ubiquitin substrate in antigen presentation 193
APC *see* Antigen-presenting cell
Apoptosis
anti-apoptotic genes 485
FasL, Bottazzo–Feldman hypothesis revisited 203
FasL, in immune privilege 240–244
in germinal centre 575
mitochondrial control of 44–51
microenvironmental control of 72–76
type B dark cells 30
Arthritis *see also* Reactive arthritis, Rheumatoid arthritis
oral tolerance in 339
Atherosclerosis
CD40–CD40L interactions in 272–277
Atopy *see* Allergy
Autoantibody
regulation in thyroid disease 437
Autoantigen
corneal, in herpes stromal keratitis 447
mapping of thyroglobulin epitopes 83–86
Autoimmune disease *see also* Autoimmunity, Experimental autoimmune encephalomyelitis, Insulin-dependent diabetes mellitus, Rheumatoid arthritis, Reactive arthritis, Thyroiditis
Bottazzo–Feldman hypothesis revisited 203
and CVID 327
C4A and protection 199 (L)
oral tolerance in treatment of 339
pathogenesis and immunotherapy of 209–211
pathology, role of endothelial cells 238
role of FcγR in 133
T-cell-mediated, treatment of 599–604
Th1 and Th2 in 266
Autoimmunity
role of anti-DNA antibodies 149–153
role of NK-cell derived TGF-β 538–542
thyrotropin-receptor mediated 437–442
Autoreactivity
of germinal centre B cells 27

B
β-catenin *see also* Tumor associated antigen
cancer regression antigen 178
β-endorphin
role in immune responses 317–319
B-1 cells
as 'living fossils' 505 (L)
B7.1
role in production of IL-4 116
in infectious disease 117
B7.2
role in production of IL-4 116
in infectious disease 117
B cell
cytokines in health and disease 343–350
immunobiology of zinc 519–521
negative signaling in 424–428
selection, glucocorticoids and 419
superantigens 379–386
B-cell activation
in atherosclerosis 274
B-cell development
in germinal centres 225–230, 573–577
IgH locus control, the enchancer shift model 549–554

B-cell proliferation
role of mast cells 214
B-cell repertoire
role of superantigens 383
B-cell tolerance *see also* Tolerance, Apoptosis
in germinal centres 27–32, 225–230
Bax
in T-cell apoptosis 72
Bcl-2 *see also* Bcl-x, Bax
apoptosis, inhibition of mitochondrial permeability transition 44–51
in T-cell apoptosis 72
Bcl-x
in T-cell apoptosis 72
Behaviour
MHC and 8–10
Biosensors
in immunology 465
Bone-marrow transplant *see also* Transplantation
for multiple sclerosis 559–561
T-cell regeneration after 245–250
Bottazzo–Feldman hypothesis
revisited, role of FasL 203
Bruton's tyrosine kinase (Btk)
in CVID 325

C
C4A *see also* Complement
and protection from autoimmune disease 199 (L)
c-Cbl
Grb2-association 404
C-reactive protein (CRP) *see also* Complement
in acute inflammation 429
in removal of injured cells 111–115
Cancer *see* Tumor immunology
Candidiasis
protective antibodies in 165
Carbohydrate
as recognition molecule 511
-binding receptors 511
therapeutic 512
CD nomenclature *see also* Leukocyte differentiation antigens
in ruminants 365–368
CD2
Schiff-base formation and 362 (L)
CD3
complex with pre-TCR 565–569
complex with TCR 565–569
CD4 T cell
lineage commitment of 261
homeostasis in HIV infection 505–507 (L), 555–556 (L)
CD5
B-1 cells as 'living fossils' 505 (L)
CD6
–ALCAM interactions 498–504
CD8 T cell
lineage commitment of 261
CD11a/CD18 (LFA-1)
in Hodgkin's disease 161
CD14
role in septic shock 333
CD28
in Hodgkin's disease 159
in T-cell IL-4 production 118
costimulation in T-cell activation 571
CD30
in Hodgkin's disease 156–163
CD31
in leukocyte migration 587, 588
CD40 *see also* CD40L, Costimulation
in atherosclerosis 272–277
on mast cells 214
CD40L
in atherosclerosis 272–277
on mast cells 214
CD45RA
in lymphocyte recirculation, a quantitative model 220
CD45R0
in lymphocyte recirculation, a quantitative model 220
CD54
in Hodgkin's disease 159
CD58
in Hodgkin's disease 159
CD59
glycosylation of 512
CD80
in Hodgkin's disease 159
costimulation in T-cell activation 571
CD86
in Hodgkin's disease 159
costimulation in T-cell activation 571
CD95 *see also* Apoptosis, Fas
CDR
CDR2 and superantigen binding 379–381
CDR3 and Ig structure and function 40–41
Cell adhesion
role of uPA 416
Cell-mediated immunity
in FIV infection 184
Chaperone
role of HLA-DM and peptide repertoire editing 77–82
Chemokine *see also* MCP-, RANTES, IL-8
fractalkine 147
regulation of endothelial-cell function 234, 235
Chemokine receptor *see* Chemokines
Chloramines
neutrophil-derived 577–580
Clinical immunology *see also* Immunotherapy
bispecific antibodies in 563
herpes stromal keratitis 443–449
Hodgkin's disease, immunological features 156–163
immunoisolation devices 135–139
markers for MS 370
modulation of β-endorphin 318
psoriasis 433–436
significance of TAP abnormalities in cancer 296
T-cell regeneration after bone-marrow transplant 248–250
TIL recognition of cancer regression antigen 179
TNF-α, suppression in sepsis 489
CLIP
HLA-DM and peptide repertoire editing 77–82
Clonal deletion
of autoreactive B cells 29
Colony-stimulating factor 1 (CSF-1)
signal transduction by 313–317
Combinatorial library
epitope structure and prediction 108–110
Common variable immunodeficiency disease (CVID)
diagnosis and scope 325–328
genetics of 326
Comparative immunology
B-1 cells as 'living fossils' 505 (L)
invertebrate phagocytes and neuroendocrine evolution 169
molecular origins of Ig genes of jawed vertebrates 543–549
Complement
C-reactive protein in inflammation 113
C4A and protection from autoimmune disease 199 (L)
European Complement Network 461
genetics 460
in human disease 460–463
in infectious disease 460
Complementarity determining region *see* CDR
Costimulation
CD40–CD40L in atherosclerosis 272–277
CTLA-4–CD80/86 in T-cell activation 571
in germinal centre reaction 574
by mast cells 214
by thymic dendritic cells 353
in Hodgkin's disease 159
Cryptic epitope
indirect allorecognition and 69
in thyroiditis 83–88
Cryptococcosis
protective antibodies in 165
CTL *see* Cytotoxic T lymphocyte
CTLA-4
in T-cell IL-4 production 118
a negative regulator of T-cell activation? 569–572
CVID *see* Common variable immunodeficiency disease
Cyclins
ubiquitin substrate in antigen presentation 195
Cytokine *see also* IL-, TNF-α, TGF-β, IFN-
in acute inflammation 429
in atherosclerosis 275
B-cell derived, in health and disease 343–350
in FIV infection 183
glucocorticoids and 418
in Hodgkin's disease 160
in infectious diseases 56–58
in peripheral tolerance 533–538
in pregnancy 478–482
in rheumatoid arthritis 320
in septic shock 329–334
regulation of endothelial-cell function 231–239
regulation of NK-cell derived TGF-β 540
role in tumor cell death 32–36
tumor-induced 493
Cytotoxic T lymphocyte (CTL)
in herpes stromal keratitis 45
immunosuppression of, in cancer 494

D
Databases
IMGT database 509
PROW 557–558
Dendritic cell (DC)
in immunotherapy 102–104
thymic dendritic cells 350–361
Differential avidity
during T-cell selection 121–126
Diffusion chambers
immunoisolation and 136
DNA fragmentation
mitochondrial control of apoptosis 44–51
DNA vaccine
in FIV 187
Doherty, Peter C.
discovery of MHC restriction 14–17

E
EAE *see* Experimental autoimmune encephalomyelitis
Endothelial cell
in allergic inflammation, regulation of 277
activation, molecular basis of 236
and CD40, in atherosclerosis 272–277
expression of protective genes 483–486
function, cytokine regulation of 231–239
leukocyte migration through, late steps 586–591
in pathology 236
Endotoxin
high-dose, in septic shock 329
low dose, in septic shock 332
Eosinophilia
inhibition by IL-10 278
Epithelial cell
in psoriasis 434
Epitope *see also* Idiotype
mapping using biosensors 466
prediction from local protein instability 527–532
structure and prediction 108–110
Epitope spreading
during indirect allorecognition 68
Evolution *see also* Comparative immunology
of Ig genes of jawed vertebrates 543–549
MHC and behaviour 8–10
neuroendocrine, invertebrate phagocytes and 169–174
Experimental autoimmune encephalomyelitis (EAE)
bone-marrow transplantation in 559–561
oral tolerance in 339
systemic antigen in therapy of 600
Eye
herpes stromal keratitis 443–449

F
Fas *see also* Apoptosis, Fas ligand, CD95
Fas ligand (FasL)
in Bottazzo–Feldman hypothesis 203
apoptosis and immune privilege in eye 240–244
expression in tumor cells 496
FcεRI
expression on APC in atopy 311–313
FcγR
-directed immunotherapy 127–135
immunoreceptor tyrosine-based inhibition motifs in 286
structure and function 127
FcRn
structure and function 592–598
Feline immunodeficiency virus (FIV)
animal model of AIDS 182–189
Fetal immunology
Th1 and Th2 in fetal allograft tolerance 264
Fibroblast *see also* Stromal cells
and CD40, in atherosclerosis 272–277
FIV *see* Feline immunodeficiency virus
Follicle
in germinal centres 225–230
Follicular dendritic cell (FDC)
in germinal centres 225–230, 573
Fractalkine
novel chemokine 147
Fungi
pathogenic 164

G
γδ T cell
surveillance function of 22–26
broad reactivity of 22
ligands for 23
Gene therapy
cytokines in cancer 32–36
Germinal centre (GC)
antigen specificity of B cells in 573–577
B-cell tolerance in 27–32
development 225–230
Glucocorticoids
immune function 418–424
Glycoimmunology
4th Jenner international meeting 511
Glycosyltransferases
in immunology 511
gp130
cytokines in inflammation 429
gp49B1
immunoreceptor tyrosine-based inhibition motifs in 288
gp100 *see also* Tumor associated antigen
cancer regression antigen 177
Granulomatous disease
and CVID 327
Granzyme B
transcription 469
Grb2
association with vav 223
signaling via CSF-1 314
in T-cell activation 401–405
Gut associated lymphoid tissue (GALT) *see also* Mucosal inflammation, Oral tolerance
in oral tolerance 336

H
Hashimoto's disease *see* Thyroiditis
Helminths
role of Th2 cells 390
Herpesvirus
herpes stromal keratitis 443–449
HIV *see also* AIDS, FIV
ceramide and (L)
gp120, epitope structure and prediction 108
immune correlates of protection 4–8
maternal–fetal transmission 3
natural immunity 5
role of polykarions 522–527
syncytia formation 522–527
T-cell homeostasis in 505–507 (L), 555–556 (L)
vaccine-induced immunity 5–7
HLA
molecular mimicry, database screening for 252 (L), 253 (L)
soluble, roles and uses 154–155
HLA class I
altered, immune surveillance of 89–94
HLA-DM
and peptide repertoire editing 77–82
HLA-DP
structure and function 58–61
Hodgkin's disease
clinical and immunological features 156–163
Human immunodeficiency virus *see* HIV

I
ICAM-1
in septic shock 331
Idiotype *see also* Epitope
anti-DNA antibodies and disease 153
of candidacidal antibodies 166
IDDM *see* Insulin-dependent diabetes mellitus
IFN-α *see also* Interferon
role in tumor immunogenicity 32–36
IFN-γ *see also* Interferon
in anti-fungal responses 164
regulation of mucosal inflammation 61–64
role in tumor immunogenicity 32–36
IgE
FcεRI expression on APC in atopy 311–313
IgG
FcγR general characteristics 129
interactions with FcRn 592
serum homeostasis 595, 596
IgM
molecular origins of 544
IgNARC *see* IgW
IgW
in jawed vertebrates 544
IgX
in jawed vertebrates 544
IL-1
B-cell derived 344
and acute inflammation 429
regulation of endothelial-cell function 231
IL-2
B-cell derived 344
in transpant tolerance 455–456 (L)
therapy and lymphocyte anergy 254 (L)

and tumor immunogenicity 32–36
in T-cell apoptosis 72
IL-4
B-cell derived 344
costimulatory molecules in production of 115–120
in anti-fungal responses 164
and tumor immunogenicity 32–36
regulation of endothelial-cell function 234
in T-cell apoptosis 72
IL-5
B-cell derived 344
and tumor immunogenicity 32–36
inhibition by IL-10 278
IL-6
and APPs as anti-inflammatory mediators 428–432
B-cell derived 344
CNS effects of 430
regulation of endothelial-cell function 233
and tumor immunogenicity 32–36
IL-7
B-cell derived 344
and tumor immunogenicity 32–36
in T-cell apoptosis 72
IL-8
B-cell derived 344
IL-10
B-cell derived 344
and tumor immunogenicity 32–36
immunotherapy of allergic inflammation 277–280
regulation of endothelial-cell function 234
tumor-derived 494
IL-12
B-cell derived 344
regulation of endothelial-cell function 234
IL-13
B-cell derived 344
regulation of endothelial-cell function 234
IL-15
in T-cell apoptosis 72
Immune deviation
in T-cell-mediated autoimmunity 600
Immune privilege
FasL-induced apoptosis in eye 240–244
FasL expression in tumor cells 496
Immune surveillance
by γδ T cells 22–26
of tumors by NK cells 90
Immunodeficiencies *see also* AIDS, Severe combined immunodeficiency
ADA deficiency in SCID 371–374
Th1 and Th2 in 264
Immunoglobulin (Ig) *see also* Antibody, Autoantibody, Immunoglobulin genes
diabodies 517
glycosylation of 513
Immunoglobulin genes
of anti-DNA antibodies 149
assembly and diversification 37
control of IgH gene expression 549–554
IgH enhancer shift 549–554
IMGT database 509
molecular evolution in jawed vertebrates 543–549
reading frame choice 37–43
V_H families in superantigen binding 382
Immunoisolation
in treating disease 135–139
Immunopathology
blindness, herpes stromal keratitis 443–449
Immunoreceptor tyrosine-based activation motifs (ITAM)
in non-receptor PTKs 395, 396
Immunoreceptor tyrosine-based inhibition motifs (ITIM)
definition of 288
receptors bearing 286–291
Immunosenescence
molecular basis 514–518
T-cell exhaustion 450–454
Immunosuppression
in cancer 493–497
Immunotherapy *see also* Tumor immunotherapy
anti-TNF-α, in rheumatoid arthritis 323, 487–492
anti-inflammatory role of α-MSH 140–145
in atherosclerosis 276
of autoimmune disease 209–211
bispecific antibodies in 562–564
of cancer 90, 102, 496
complement in 462
dendritic cells in 102–104
FcγR-directed 127–135
FcRn-directed 597
IL-2, and lymphocyte anergy 254 (L)
IL-10 in allergic inflammation 277–280
immunoisolation in treating disease 135–139
in MS 370
oral tolerance and autoimmune disease 335–343
peptide-based, in transplantation 69
for recurrent spontaneous abortion 481
systemic antigen in autoimmunity 599–604
targets in late T-cell activation 469
using thymic peptides 10–13
using zinc 521
Infectious disease
B7 costimulation in 117
cytokines in 56–58
FcγR in 131
pathology, role of endothelial cells 236
Inflammation *see also* Immunotherapy
anti-inflammatory role of α-MSH 140–145
anti-inflammatory role of IL-6 and APRs 428–432
gene-expression in endothelial cells 433–486
TNF-α, suppression of 487–492
Innate immunity
B-1 cells as 'living fossils' 505 (L)
neutrophil chloramines 577–580
role of γδ T cells 22–26
role of mast cells 212
Insulin-dependent diabetes mellitus (IDDM)
oral tolerance in 340
systemic antigen in therapy of 602
Interferon (IFN-) *see also* IFN- α, β, γ
B-cell derived 344
regulation of endothelial-cell function 234
Interleukins *see also* Cytokine, IL-1–18
in Hodgkin's disease 160
gene therapy in cancer 32–36
Isotype switching
and B-cell maturation in germinal centre 575
ITAM *see* Immunoreceptor tyrosine-based activation motifs
ITIM *see* Immunoreceptor tyrosine-based inhibition motifs

K
Keratinocytes
role in psoriasis 434
Killer-cell inhibitory receptor (KIR)
immunoreceptor tyrosine-based inhibition motifs in 286
on NK cells in reproduction 65
ontogeny of 146 (L)
KIR, *see* Killer cell inhibitory receptor
Knockout mice
IL-6, and acute inflammation 429
in studies of complement 461
in studies of germinal centre reaction 229
in studies of septic shock 329–334
Koebner phenomenon *see* Psoriasis

L
Langerhans cells *see also* Antigen-presenting cells
production of NO in psoriasis 433–436
Leishmania
role of cytokines in 56
Leukocyte differentiation antigens
bovine 365
ovine 365
in ruminants 365–368
Leukocyte migration
late steps in 586–591
stepwise model of 590
LFA- *see* CD11a/CD18
Locus control region (LCR)
in IgH genes 552
Lymphocyte development
recent advances in 260–262
Lymphocyte migration *see also* Leukocyte migration
role of uPA 417
Lymphocyte recirculation
quantitative model of 216–221
Lymphocyte trafficking *see* Leukocyte migration, Lymphocyte migration
Lymphoma
Hodgkin's disease 156–163

M
Macrophage
and CD40, in atherosclerosis 274
anti-inflammatory role of α-MSH 141
communication with neutrophils 577
invertebrate phagocytes and neuroendocrine evolution 169–174
-like CD5 B cells 505 (L)

Major histocompatibilty complex (MHC) *see also* MHC class I, MHC class II
assembly of 269–271
and behaviour 8–10
molecular mimicry, database screening for 252 (L), 253 (L)
discovery of 14–17
immunodominance of low-affinity epitopes 97 (L), 98 (L)
indirect T-cell allorecognition 67–71
serial engagement of TCR 299–304
soluble HLA antigens 154–155
Malaria
role of Th1 cells 388
Marker assisted selection protocols
in speed congenic mice 472
MART-1 *see also* Tumor associated antigen
cancer regression antigen 176
Mast cell
effector mechanisms 212
function in immune responses 212–215
Maternal-fetal interface *see also* Reproductive immunology
structure and function of FcRn 592–598
transfer of IgG 595
Matrix attachment region (MAR)
in IgH locus 550
Mathematical model *see* Quantitative model
α-Melanocyte stimulating hormone (α-MSH)
anti-inflammatory actions 140–145
α-MSH receptors 140
Membrane lipids
flip-flop during acute phase response 111
Memory
in antiviral immunity 258
T cells, migration of 456 (L)
Meo, Tommy
obituary 411
MHC *see* Major histocompatibility complex
MHC class I
association with TAP 375–379
-related receptor, FcRn 592–598
TAP processing, abnormalities in cancer 292–299
on trophoblast 65
MHC class II
function of HLA-DP 58–61
HLA-DM and peptide repertoire editing 77–82
peptides and superantigen 18–22
peptide epitope prediction 527–532
ligation of TCR/CD3 complex, a model 566
Microbial immunity
cytokines in infectious diseases 56–58
Microchimerism
and transplant tolerance 455–456 (L)
Microreactors
and immunoisolation devices 138
Mitochondria
control of apoptosis 44–51
permeability transition 46–49
Molecular immunology
future perspectives in 516
Molecular mimicry
in autoimmunity 96 (L)
database screening for 252 (L), 253 (L)
'shared motif' hypothesis 95–96 (L)
Monocytes
immunobiology of zinc 519
MS *see* Multiple sclerosis
Mucins
carcinoma associated, structure and function 105–107
T-cell recognition of 267–268
Mucosal inflammation
regulation by IFN-γ and TGF-β 61–64
TNF-α, suppression in Crohn's disease 490
Multinucleated giant cells
polykarions in the immune response 522–527
Multiple sclerosis (MS)
bone-marrow transplantation for 559–561
histopathology 368
genetics of 369
recent advances in 368–371
Th-cell modulation in 507 (L)
viral association 369
Multivalent antigens
and cell-surface antibodies 305 (L), 306 (L)
Myasthenia gravis (MG)
oral tolerance in 339
Myelin basic protein (MBP) *see also* Multiple sclerosis
in MS pathology 368
Myelin oligodendrocyte glycoprotein antigen in MS 368

N

Natural killer (NK) cell
coordinate regulation with CTL
immunosenescence of 514
NK-cell derived TGF-β in autoimmunity 538–542
ontogeny of KIRs 146 (L)
in reproduction 64–66, 605 (L)
tumor-cell recognition 90
Negative selection
of γδ T cells 261
of germinal centre B cells 28
role of thymic dendritic cells 357, 358
Neuroimmunology
anti-inflammatory role of α-MSH 140–145
complement in neurological disease 462
glucocorticoids and immune function 418–424
invertebrate phagocytes and neuroendocrine evolution 169–174
and psoriasis 435
Neutral endopeptidase (NEP)
role in septic shock 333
Neutrophil
anti-inflammatory role of α-MSH 141
chloramines, in immunity 577–580
communication with macrophages 577
role in rheumatoid arthritis 320–324
role in septic shock 331
mechanism of cartilage damage 321
New antigen receptor (NAR)
in jawed vertebrates 544
NF-IL-6
in T-cell activation 470
NF-κB
ubiquitin substrate in antigen presentation 195
Nitric oxide (NO) *see also* Nitric oxide synthase
in invertebrate phagocytes 171
in endothelial-cell function 232
in psoriasis 433–436
Nitric oxide synthase
in endothelial-cell function 232
Nuclear Magnetic Resonance
in epitope prediction 527–532
Nutrients
immunobiology of zinc 519–521

O

Oculo-mucocutaneous disorders
herpes stromal keratitis 443–449
Olfaction
MHC and behaviour 8–10
Oral tolerance
bystander suppression in 337
IFN-γ and TGF-β in mucosal inflammation 61–64
immune mechanisms 335–339
treatment of autoimmune disease 339–343

P

p15 *see also* Tumor associated antigen
cancer regression antigen 176
p53
ubiquitin substrate in antigen presentation 193
Parasite immunity
role of cytokines in 56–58
Th1/Th2 responses in 387–392
Pathogenesis
fungal 164–169
Hodgkin's disease, viral etiology 157
neutrophil-mediated, in rheumatoid arthritis 321
superantigens in disease 384
Pentraxins
serum amyloid P 112
Peptide
loading of MHC class I 376
Perfusion devices
immunoisolation and 136
Perforin *see also* Granzyme B
transcription 469
Peripheral tolerance
T-cell deletion in autoimmunity 600
Phage-display *see* Combinatorial library
Phagocyte
invertebrate, neuroendocrine evolution and 169–174
Phosphoinositide 3-kinase (PI 3-kinase)
activation by CSF-1 314
Phospholipase A_2
secretory, in removal of injured cells 111–115
Phospholipase C
and signaling via CSF-1 316

Phosphorylation
ligands for γδ T cells 23
of vav, role in hematopoiesis 222
Phylogeny
of Ig genes 543–549
Placental suppressor factor
role in pregnancy 480
Polykarions
in immune responses 522–527
Positive selection
in reaggregate thymus organ culture 364
of γδ T cells 261
of pre-B and -T cells 261
role of low-affinity T-cell epitopes 97 (L), 98 (L)
pp36
association with Grb2 402
Pregnancy
loss of, role of Th1-type response 478–482
natural killer cells in 64–66, 605 (L)
Pre-T-cell receptor *see also* T-cell receptor
Progesterone-induced blocking factor
role in pregnancy 480
Programmed cell death *see* Apoptosis
Protease
inhibitors of 269
Proteasome
abnormalities in cancer 293
ubiquitination and antigen presentation 196
viral evasion of 270
Proteinases
in leukocyte migration 590
Protein kinase C (PKC)
and signaling via CSF-1 316
in psoriasis 433
Protein tyrosine kinase (PTK) *see also* Phosphorylation, Signaling
non-receptor-, as viral targets 393–400
Psoriasis
NO production by Langerhans cells in 433–436

Q
Quantitative model
for antigen–antibody dissociation 305 (L), 306 (L)
T-cell epitope prediction 527–532
immunity, ecology and populations 517
of lymphocyte recirculation 216–221
for marker assisted selection protocols 472
for serial engagement of TCR 302
for TCR/CD3 complex signaling 565–569
for thymopoiesis 581–585

R
RANTES
role in T-cell maturation 468–471
Ras
and signaling via CSF-1 315
negative signaling in B cells 426
Reactive oxygen intermediates (ROI)
neutrophil dependent, in rheumatoid arthritis 322
reactive chloramines 578
Replicative senescence
T-cell exhaustion 450–454
Reproductive immunology
NK cells in 64–66, 605 (L)
Th1-type immunity and pregnancy loss 478–482
Rheumatoid arthritis (RA)
anti-inflammatory role of α-MSH 144
role of complement 462
role of neutrophils 320–324
TNF-α, suppression of 490

S
SAg *see* Superantigen
Scavenger receptor
CD6–ALCAM interactions 498–504
Schiff-base formation
in cell–cell interaction 362 (L)
SCID *see* Severe combined immunodeficiency
Selectin *see* Adhesion molecule
Septic shock
glucocorticoids and 419
mechanisms 329–334
TNF-α, suppression of 488
Severe combined immunodeficiency (SCID)
role of ADA deficiency 371–374
Shc
and signaling via CSF-1 314
Grb2-association 401–405
SHIP
negative signaling in B cells 425
SHP-1
and signaling via CSF-1 314
negative signaling in B cells 425
Signaling
abnormalities in cancer 292–299
ADA deficiency in SCID 371–374
via CSF-1 313–317
during leukocyte migration 589
Grb2-associated, in T-cell activation 401–405
immunoreceptor tyrosine-based inhibition motifs 286–291
negative, in B cells 424–427
positive, in B cells 424
Schiff-base formation and 362 (L)
TCR, role in thymic organization 204–208
uPA, -receptor, -inhibitor 415–417
vav, role in hematopoiesis 221–225
viral targeting of non-receptor PTKs 393–400
Simian immunodeficiency virus *see* SIV
SIV *see also* AIDS, HIV
T-cell homeostasis in 555–556 (L)
SLP-76
in T-cell activation, association with Grb2 403
Sos
association with Grb2 401
association with vav 222
signaling, role in hematopoiesis 221–225
Stress
invertebrate phagocytes and 172
Stromal cells *see also* Endothelial cells, Fibroblast
in reaggregate thymus organ culture 363
T-cell rescue from AICD 73–75
Sugars *see* Carbohydrate
Superantigen (SAg)
B-cell 379–386
bacterial 18
peptide presentation and 18–22
peptide mimicry 20
Syncytia
HIV-induced 522–527

T
T cell *see also* γδ T cell
involvement in Hodgkin's disease 158
naive and memory, migration of 456 (L)
T-cell activation
in atherosclerosis 273
in immunosenescence 514
negative regulation by CTLA-4 569–572
role of RANTES 468–471
role of Grb2-associated proteins 401–406
serial engagement of TCR in 299–304
and tolerance 536
T-cell development
glucocorticoids and 419
RANTES in late transcription 468–471
T-cell epitope *see* also Epitope
prediction from local protein instability 527–532
T-cell exhaustion
immunosenescence 514–516
replicative senescence 450–454
in AIDS 505–507 (L), 555–556 (L)
T-cell differentiation
glucocorticoids and 419
T-cell epitope
epitopes with low-affinity for MHC 97 (L), 98 (L)
T-cell memory
impact of replicative senescence 453
rescue from AICD and 75
T-cell migration
naive versus memory 456 (L)
in gut associated lymphoid tissue 335
T-cell receptor (TCR) *see also* Pre-T-cell receptor
agonist–antagonist balance and positive selection 121–126
genes, IMGT database 509
incompletely assembled, degradation of 271
serial engagement of 299–304
signaling and regulation of thymic organisation 204–208
complex with CD3, a model for signaling 565–569
transgenic mice 204–208
T-cell regeneration
thymic dependent 245
thymic independent 245
T-cell repertoire
generation of 260
immunodominance of low-affinity epitopes 97 (L), 98 (L)
in reaggregate thymus organ culture 363
regeneration of 245–251

T-cell rescue
from AICD 74
T-cell selection
glucocorticoids and 419
role of low-affinity T-cell epitopes 97 (L), 98 (L)
T-cell tolerance *see* Peripheral tolerance, Tolerance
TAP
abnormalities in cancer 292–299
association with MHC class I 375–379
TCR *see* T-cell receptor
TCR repertoire *see* T-cell repertoire
Techniques
biosensors in immunology 464–467
IMGT database 509
marker assisted selection protocols 472
nuclear magnetic resonance in epitope prediction 527–532
speed congenic mice 472–477
Telomerase
in replicative senescence of T cells 451
TGF-β
B-cell derived 344
NK-cell derived, in autoimmunity 538–542
regulation of mucosal inflammation 61–64
tumor-induced 493
Th1/Th2 paradigm
current advances in 263–266
dangerous dogma? 387–392
glucocorticoids and 419
in pregnancy 478
Th1 cell
balance in autoimmunity 209–211
dominant responses 263
in herpes stromal keratitis 443–449
interaction with mast cells 214
modulation in MS 507 (L)
in peripheral tolerance 533–538
polarizing signals 263
protection against intracellular pathogens 387
role of β-endorphin in immune responses 317
Th2 cell
balance in autoimmunity 209–211
costimulation and differentiation 115
dominant responses 263
in herpes stromal keratitis 446
interaction with mast cells 214
modulation in MS 507 (L)
in peripheral tolerance 533–538
polarizing signals 263
protection against extracellular pathogens 389
role of β-endorphin in immune responses 317
Th1-type cytokine
balance in autoimmunity 209–211
and pregnancy loss 478–482
Th2-type cytokine
balance in autoimmunity 209–211
Thymic dendritic cells
phenotype and function 350–361
Thymic development
'disposable soma' and involution 407 (L)
regulatory feedback pathways 581–585
role of thymic dendritic cells 350–361
role of thymic stromal cells 363
TCR signaling in transgenic mice 204–208
Thymic epithelium
'disposable soma' and involution 407 (L)
in reaggregate thymus organ culture 363
stromal-cell organization in transgenic mice 204–208
thymic dendritic cells 350–361
Thymic humoral factor (THF) *see* Thymic peptides
Thymic peptides
and immunotherapy 10–13
Thymocyte
differentiation 355
regeneration after bone-marrow transplant 245–250
selection, glucocorticoids and 419
Thymopentin *see* Thymic peptides
Thymopoietin *see* Thymic peptides
Thymosin *see* Thymic peptides
Thymulin *see* Thymic peptides
Thymus *see* Thymic
Thyroglobulin
pathogenic epitopes 83–88
Thyroiditis
thyroglobulin epitopes 83–88
thyrotropin-receptor-mediated disease 437–442
Thyrotropin
-receptor in autoimmunity 437–442
Thyrotropin receptor
structure and function in autoimmunity 437–442
TNF-α
B-cell derived 344
regulation of endothelial-cell function 231
role in tumor immunogenicity 32–36
suppression of 487–492
target for immunotherapy in autoimmunity 210
target for immunotherapy of rheumatoid arthritis 323
tumor resistance to 495
TNF-receptor (TNFR)
soluble, in inflammation 429
TNFR1 in septic shock 332
Tolerance *see also* Anergy, Oral tolerance, Peripheral tolerance
in autoimmune disease, role of systemic antigen 599–604
CD4 T cells in 533–538
CTLA-4 in 570
cytokines in 533–538
in germinal centres 27–32
and immune privilege, FasL-induced 242
role of soluble antigen 28
Toxins
yeast killer toxins 164–169
Transcription factors
in activation of endothelial cells 233–235, 484
arrest in septic shock 332
cis-acting elements in IgH locus 550
NF-IL-6 470
octamer-binding factors in B-cell development 551
R(A)FLAT 470
R(C)FLAT 470
RANTES in T-cell maturation 468–471
Transforming growth factor β *see* TGF-β
Transgenic mice
TCR, and thymic development 204–208
in studies of germinal centre reaction 229
Transplantation *see also* Bone-marrow transplant, Xenotransplant
and immune privilege 243
indirect T-cell allorecognition and immunotherapy 69
oral tolerance in 339
pathology, role of endothelial cells 238
tolerance microchimerism 455–456 (L)
Trophoblast
as NK-cell target 65
-derived factor, role in pregnancy 480
Tumor associated antigen (TAA) *see also* Vaccine
cancer regression antigens 175–182
in melanoma 176
immunogenicity, enhanced by natural anti-Gal antibody 281
low-affinity T-cell epitopes 97 (L), 98 (L)
T-cell recognition of 267–268
Tumor immunology *see also* Tumor associated antigens
carcinoma associated mucins 105–107
cytokines, from neoplastic B-cells 346
future perspectives in 518
host–tumor interaction 493–497
immune surveillance of altered MHC class I 89–94
neoplasia, role of endothelial cells 237
role of complement 462
TAP abnormalities in cancer 292–299
Th1/Th2 responses 391
tumor growth factors 495
Tumor immunotherapy
bispecific antibodies in 563
dendritic cells in 102–104
FcγR-directed immunotherapy 128
natural anti-Gal antibody to augment tumor vaccines 281–284
vaccine based on cancer regression antigens 175–182
vaccines based on tumor associated antigens 268
Tumor infiltrating lymphocytes (TIL)
use in identification of cancer regression antigens 175
Tumor necrosis factor *see* TNF
Tyrosinase *see also* Tumor associated antigen
cancer regression antigen 178
Tyrosinase-ralated protein 1 (TRP1) *see also* Tumor associated antigen
cancer regression antigen 178

U
Ubiquitin
protein degradation and antigen presentation 189–198
substrates 191
Ubiquitination
role in antigen presentation 189–198
Urokinase plasminogen activator (uPA)
-receptor 415–417
-inhibitor 415–417

V
V-D-J recombination
D-gene reading frame choice 37–43
Vav
associated proteins 222
nuclear function of 223
signaling, role in hematopoiesis 221–225
structure 222
Vaccines
antigen presentation and 'danger' 413
antiviral 259
based on cancer regression antigens 175–182
delivery of 414
DNA, in FIV 187
future perspectives in 518
FIV 185
immunization in the neonate 413
immunopathology and 414
subunit, in FIV 184
Viral immunology *see also* Antiviral immunity
targeting non-receptor PTKs 393–400

X
X-linked agammaglobulinaemia (XLA) and CVID 325
X-linked hyper-IgM syndrome (X-HIM) and CVID 325
Xenotransplant
rejection, gene expression in endothelial cells 433–486

Y
Yeast
killer toxins 164–169

Z
Zinc
immunobiology of 519–521
Zinkernagel, Rolf M.
discovery of MHC restriction 14–17

Index of Books Reviewed

B

Bach, F.H. and Auchincloss, H. Jr, eds, *Transplantation Immunology* 409

Brent, L., *A History of Transplantation Immunology* 409

Browning, M. and McMichael, A., eds, *HLA and MHC: Genes, Molecules and Function* 200

D

Davidson, T.F., Morris, T.R. and Payne, L.N., eds, *Poultry Immunology* 307

G

Grabowski, R., *The Web Publisher's Illustrated Quick Reference* 457

H

Honjo, T. and Alt, F.W., eds, *Immunoglobulin Genes (2nd edn)* 200

I

Iwama, G. and Nakanishi, T., eds, *The Fish Immune System: Organism, Pathogen, and Environment* 556

J

Janeway, C.A. and Travers, P., *Immunobiology: The Immune System in Health and Disease (2nd edn)* 201

L

Lanza, R.P., Langer, R. and Chick, W.L., *Principles of Tissue Engineering* 407

Lieberman, P. and Anderson, J.A., eds, *Allergic Diseases: Diagnosis and Treatment* 408

N

Neilson, E.G. and Couser, W.G., *Immunologic Renal Diseases* 508

R

Rinkevich, B. and Müller, W.E.G., eds, *Invertebrate Immunology* 199

Rosen, F.S. and Geha, R.S., O'Gorman, M.R.G., *Case Studies in Immunology: A Clinical Companion* 254

W

Wakelin, D., ed, *Immunity to Parasites: How Parasitic Infections are Controlled (2nd edn)* 255

TECHNICAL TIPS ONLINE

Bags of free tips for molecular biologists

A unique online journal of peer-reviewed molecular biology techniques articles

http://www.elsevier.com/locate/tto
in Europe http://www.elsevier.nl/locate/tto

KEY FEATURES

- free to use
- coverage of: PCR, gene expression, cloning & sequencing, and much more
- discussion/feedback for all articles
- rapid publication
- EMBASE/MEDLINE abstracts
- information about products cited in articles
- new product information

http://www.elsevier.com/locate/tto
in Europe http://www.elsevier.nl/locate/tto






ELSEVIER TRENDS JOURNALS TECHNICAL TIPS ONLINE
ARTICLE IMAGE
A simple procedure to increase efficiency of
DEAE-dextran transfection of COS cells

ELSEVIER TRENDS JOURNALS